New drugs for tuberculosis

Bibliography

• SENSI P, GIALDRONI GRASSI G: Antimycobacterial agents. In: Burger's Medicinal Chemisby and DrugDiscovoyVol. 2: Therapeutic Agents. Wolff ME (Ed.), John Wiley and Sons, Inc., New York (1996):575–636.
   Google Scholar
• A comprehensive review of antimycobacterial agents with a detailed analysis of chemical development and in vitro and in vivo activity of each derivative. The apects of pathogenesis, epidemiology and treatment of TB are also taken into consideration (518 references).
   Google Scholar
• CENTERS FOR DISEASE CONTROL AND PREVENTION: Tuberculosis morbidity. Morbid. Mortal. Weekly Rep. 1993 (1992) 42:696-704.
   Google Scholar
• Figures given in this CDC report provide information on the epidemiology of TB and its evolution over time.
   Google Scholar
• CENTERS FOR DISEASE CONTROL AND PREVENTION: Estimates of future global tuberculosis morbidity and mortality. Morbid. Mortal. Weekly Rep. (1993) 21:167–187.
   Google Scholar
• As with the other CDC reports, the information can be used to follow the epidemiology of TB.
   Google Scholar
• KOCHI A: The global tuberculosis situation and the new control strategy of the World Health Organization. Tubercle (1991) 72:1–6.
   PubMedGoogle Scholar
• A very informative paper outlining the WHO's strategy for TB containment.
   Google Scholar
• SELWYN PA, HARTEL D, LEWIS IA: A prospective study of the risk of tuberculosis among intravenous drug abus-ers with human immunodeficiency virus infection. New Engl. J Med. (1989) 320:545–550.
   PubMed Web of Science ®Google Scholar
• NARAIN JP, RAVIGLIONE MC, KOCHI A: HIV-associated tuberculosis in developing countries: burden, interven-tion and strategies for prevention. Tuberc. Lung Dis. (1992) 73:311–32.
   PubMedGoogle Scholar
• In this paper, the problem of HIV-associated tuberculosis in devel-oping countries is analysed.
   Google Scholar
• WORLD HEALTH ORGANIZATION: Proposed tuberculo- sis control programme work plan and budget 1992–1993. World Health Organization, Geneva.
   Google Scholar
• The plan and budget of the WHO's programme for the containment of TB, outlining the implementation of directly observed therapy (DOT).
   Google Scholar
• BAYER R, WILKINSON D: Directly observed therapy for tuberculosis: history of an idea. Lancet (1995) 345:1545–1548.
   PubMed Web of Science ®Google Scholar
• Interesting review of all the efforts which have been undertaken since the fifties to obtain the compliance of patients.
   Google Scholar
• O'BRIEN RJ: The treatment of tuberculosis. In: Tubercu- losis. A comprehensive international approach. Reichamn LB, Hershfield ES (Ed.), Marcel Dekker, Inc. New York (1993) 207–240.
   Google Scholar
• Exhaustive review of TB therapies, providing a complete overview of the basic and practical aspects of tuberculosis.
   Google Scholar
• BARNES PF, BARROWS SA: Tuberculosis in the 1990s. Ann. Intern. Med. (1993) 119:400–410.
   PubMed Web of Science ®Google Scholar
• Very good review of the problems associated with the treatment of TB.
   Google Scholar
• CENTERS FOR DISEASE CONTROL: National action plan to combat multi drug-resistant tuberculosis. Meeting the challenge of multi-drug-resistant tuberculosis: sum-mary of a conference; management of persons exposed to multi drug-resistant tuberculosis. Morbid. Mortal. Weekly Rep. (1992) 41 (RR-11) :1–71.
   Google Scholar
• Paper outlining the CDC programme to combat multidrug-resistant (MDR) TB.
   Google Scholar
• PRIGNOT J: Multi drug-resistance of tubercle bacilli-Facts and implications for National Programmes. IUTLD Newslett (1993) 1–6.
   Google Scholar
• BLOCH AB, CAUTHEN GM, ONORATO IM et al.: Nation- wide survey of drug-resistant tuberculosis in the United States. JAMA (1994) 271:665–671.
   PubMed Web of Science ®Google Scholar
• Useful information on the diffusion of MDR strains of M. tuberculosis.
   Google Scholar
• HYMAN CL: Tuberculosis: a survey and review of current literature. CUIT. Opin. Pulmon. Med. (1995) 1:234-242. Concise, but exhaustive review of TB.
   Google Scholar
• ZIMENT I: Epidemiology of mycobacterial infection to- ?day. Eur. Resp. Rev. (1995) 5:91-97. Very good epidemiological survey.
   Google Scholar
• GANGADHARAM PRJ: Drug resistance in tuberculosis. In: Tuberculosis. A comprehensive International Approach.Reichamn LB, Hershfield ES (Eds.), Marcel Dekker, Inc., New York (1993):293–328.
   Google Scholar
• A very good survey of the epidemiological aspects of drug resistance in TB. See also [9].
   Google Scholar
• HOUSTON S, FANNING D: Current and potential treat- ment of tuberculosis. Drugs (1994) 46:689–708.
   Google Scholar
• A thorough review dealing with all the aspects of TB treatment, including cost.
   Google Scholar
• CENTERS FOR DISEASE CONTROL: Outbreak of mul-tidrug-resistant tuberculosis. Morbid. Mortal. Weekly Rep.(1990) 39:369–372.
   PubMedGoogle Scholar
• SNIDER DE, CAUTHEN GM, FARER JO et al: Drug resistant tuberculosis. Am. Rev. Resp. Dis. (1991) 144:732.
   PubMed Web of Science ®Google Scholar
• ETKIND SC: Contact tracing in tuberculosis. In: Tubercu-losis. A comprehensive International Approach. Reichamn LB, Hershfield ES (Eds.), Marcel Dekker, Inc., New York (1993):275–289.
   Google Scholar
• AMERICAN THORACIC SOCIETY: Treatment of tuberculo- ?sis and tuberculosis infection in adults and children. Am. J. Resp. Grit. Care Med. (1994) 194:1359–1374.
   Google Scholar
• Guidelines issued by the American Thoracic Society outlining TB regimens. This document outlines the global aspects of treatment, the characteristics of each drug and the evaluation of adverse reactions.
   Google Scholar
• ISEMAN MD: Treatment of multidrug resistant tubercu- losis. New Engl. J. Med. (1993) 329:784–791.
   PubMed Web of Science ®Google Scholar
• Guidelines for TB treatment.
   Google Scholar
• CENTERS FOR DISEASE CONTROL (CDC): Initial therapy for tuberculosis in the era of multidrug resistance. Recommendations for the Advisory Council for the elimination of tuberculosis. Morbid. Mortal. Weekly Rep. (1993) 42(N.RR-7):1–7.
   Google Scholar
• HOPEWELL PC: Tuberculosis and infection with the human immunodeficiency virus. In: Tuberculosis. A com- prehensive international approach. Reichamn LB, Hershfield ES (Eds.), Marcel Dekker, New York (1993) 369–394.
   Google Scholar
• This article deals with the frightening aspects of the diffusion of TB, particularly in developing countries and in HIV-infected patients.
   Google Scholar
• KUNIN CM: Antimicrobial activity of rifabutin. Olin. Infect. Dis. (1996) 22 (Suppl. 1) :S3–S14
   Google Scholar
• GRASSI C, PEONA V: Use of rifabutin in the treatment of pulmonary tuberculosis. Olin. Infect. Dis. (1996) 22\(Suppl. 1):S50–S54.
   Google Scholar
• Up-to-date review of clinical trials with rifabutin.
   Google Scholar
• YEU WW, CHAN CH: New antimycobacterial agents. Monaldi Arch. (1996) 51:394-404. Good review of novel antimycobacterial agents.
   Google Scholar
• BERMUDES LE, YOUNG LS. New drugs for the therapy of mycobacterial infections. Curr. Opin. Infect. Dis. (1995) 8:428–437.
   Web of Science ®Google Scholar
• Accurate review of novel agents for TB, leprosy and Mycobacterium avium complex.
   Google Scholar
• GRASSI C, PEONA V: New drugs for tuberculosis. Eur. Resp. J. (1995) 5 (Suppl. 20) :714s–718s.
   Google Scholar
• Complete review of novel drugs for TB and the synthesis of these drugs.
   Google Scholar
• BAKER WR, MITSCHER LA, ARAIN TM, SHAWAR R, STOVER CK: Recent advances in the chemistry and biology of antimycobacterial agents. In: Annual Reports in Medicinal Chemistry Bristol JA (Ed.), Academic Press, San Diego (1996) 31:161–170.
   Web of Science ®Google Scholar
• The development of novel agents from the chemical point of view.
   Google Scholar
• SENSI P: Approaches to the development of new antitu- berculous drugs. Rev. Infect. Dis. (1989) 11 (Suppl. 2):S467–S470.
   Google Scholar
• Possible novel targets for TB treatment are reviewed.
   Google Scholar
• YOUNG DB: Strategies for new drug development. In: Tuberculosis. Pathogenesis, protection and control . Bloom BR(Ed.), ASM Press, Washington DC (1994) 559–568.
   Google Scholar
• Novel strategies for the development of TB therapies are dealt with on the basis of recent findings in molecular biology.
   Google Scholar
• COLE ST, SMITH DR: Toward mapping and sequencing the genome of Mycobacterium tuberculosis. In: Tuber-culosis. Pathogenesis, protection and control. Bloom BR (Ed.), ASM Press, Washington, DC (1994) 227–238.
   Google Scholar
• Excellent review outlining the mapping and sequencing of the M tuberculosis genome, which is in progress.
   Google Scholar
• ZHANG Y, HEYM B, ALLEN B, COLE ST: The catalase-per- oxidase gene and isoniazid resistance of Mycobac- terium tuberculosis. Nature (1992) 358:591–593.
   PubMed Web of Science ®Google Scholar
• This article discusses the implications of the finding that the activity of isoniazid depends on the presence of a catalase peroxidase enzyme.
   Google Scholar
• BANERJEE A, DUBNAU E, QUEMARD V et al.: MA, a gene encoding a target for isoniazid and ethionamide inMycobacterium tuberculosis. Science (1994) 263:227–230.
   PubMed Web of Science ®Google Scholar
• This paper outlines another important discovery in the under-standing of the mechanism of action of isoniazid.
   Google Scholar
• SILVE G, VALERO-GUILLEN P, QUEMARD A, DUPONT MA, DAFFE M, LANCELE G. Etharnbutol inhibition of glucose-metabolism in Mycobacteria: a possible target of the drug. Antimicrob. Agents and Chemother. (1993) 37:1536–1538.
   PubMed Web of Science ®Google Scholar
• This paper refers to the most recent discoveries in the field of antimycobacterial resistance as well as to the mechanism of action of TB drugs.
   Google Scholar
• BELANGER AE, BESZA GS, FORD et al.: The embAB genes of Mycobacterium avium encode an arabinosyl trans-ferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol. Proc. Natl. Acad. Sci. USA (1996) 21:11919–11924.
   Google Scholar
• This paper refers to the most recent discoveries in the field of antimycobacterial resistance as well as to the mechanism of action of TB drugs.
   Google Scholar
• ROUSE DA, MORRIS SL: Molecular mechanisms of isoniazide resistance in Mycobacterium tuberculosis and Mycobacterium bovis. Infect. Immun. (1995) 63:1427–1433.
   PubMed Web of Science ®Google Scholar
• This paper refers to the most recent discoveries in the field of antimycobacterial resistance as well as to the mechanism of action of TB drugs.
   Google Scholar
• TELENTI A, PHILIPP W, SREEVATSAN S et al.: The emb operon: a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol. Nature Med. (1996) 3:567–570.
   Web of Science ®Google Scholar
• This paper refers to the most recent discoveries in the field of antimycobacterial resistance as well as to the mechanism of action of TB drugs.
   Google Scholar
• FINKEN M, KIRSCHNER P, MEIER A, VVREDE A, BOTTGER EC: Molecular basis of streptomycin resistance in the ribosomal tuberculosis: alterations of the ribosomal protein S12 gene and point mutations within the func-tional 16S ribosomal RNA pseudoknot. Mot. Microbiol. (1993) 47:467–501.
   Google Scholar
• This paper refers to the most recent discoveries in the field of antimycobacterial resistance as well as to the mechanism of action of TB drugs.
   Google Scholar
• NAIR J, ROUSE DA, BAI GH, MORRIS SL: The rps gene and streptomycin resistance in single and multiple drug resistant strains of Mycobacterium tuberculosis. Mot. Nlicrobiol (1993) 10:521–527.
   PubMed Web of Science ®Google Scholar
• This paper refers to the most recent discoveries in the field of antimycobacterial resistance as well as to the mechanism of action of TB drugs.
   Google Scholar
• HONORE N, COLE ST: Streptomycin resistance in myco- bacteria. Antimicrob. Agents Chemother. (1994) 38:238-242. This paper refers to the most recent discoveries in the field of antimycobacterial resistance as well as to the mechanism of action of TB drugs.
   Google Scholar
• TAKIFF HE, SALAZAR L, GUERRERO C et al.: Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resis-tance mutations. Antimicrob. Agents Chemother. (1994) 38:773–780.
   PubMed Web of Science ®Google Scholar
• This paper refers to the most recent discoveries in the field of antimycobacterial resistance as well as to the mechanism of action of TB drugs.
   Google Scholar
• TELENTI A, IMBODEN P, MARCHESI F et al.: Detection of rifarnpicine-resistance mutations inMycobacterium tu-berculosis. Lancet (1993) 341:647–652.
   PubMed Web of Science ®Google Scholar
• This paper refers to the most recent discoveries in the field of antimycobacterial resistance as well as to the mechanism of action of TB drugs.
   Google Scholar
• FALKINHAM JO, CRAWFORD JT: Plasmids. In: Tuberculosis. Pathogenesis, Protection and Control. Bloom BR (Ed.), ASM Press, Washington DC (1994):185–198.
   Google Scholar
• RASTOGI N, ROSS BC, DWYER B et al: Emergence during unsuccessful chemotherapy of multiple drug resistance in a strain of Mycobacterium tuberculosis. Eur. J GM. Nlicrobiol. Infect. Dis. (1992) 11:901–907.
   PubMed Web of Science ®Google Scholar
• HEYM B, HONORE N, TRUFFOT-PERNOT C et al.: Irnplica- tions of multidrug resistance for the future of short-course chemotherapy of tuberculosis: a molecular study. Lancet (1994) 344:293–298.
   PubMed Web of Science ®Google Scholar
• The implications of multidrug resistance and the applications of short course therapy are analysed.
   Google Scholar
• TEN DAM HG: BCG Vaccination. In: Tuberculosis. A com-
   Google Scholar
• ?prehensive international approach. Reichamn LB, Hershfield ES (Eds.), Marcel Dekker, New York (1993): 251–274. An exhaustive review of 70 years' experience with BCG.
   Google Scholar
• BLOOM BR, FINE EM: The BCG experience: implication for future vaccines against tuberculosis. In: Tuberculosis.Pathogenesis, Protection and Control. Bloom BR (Ed.), ASM Press, Washington DC (1994):531–557.
   Google Scholar
• A careful analysis of the BCG vaccine and the prospects for the development of improved vaccines.
   Google Scholar
• STANDFORD JL, BAHR GM, BAYSS et al.: A modern ap-proach to immunotherapy of tuberculosis. Bull. Int. Union Tuber. Lung Dis. (1990) 65:27–29.
   PubMedGoogle Scholar
• HACHEM R, ROAD J, ROLSON VI et al.: Cutaneous and pulmonary infections caused by Mycobacterium vac-cae. Clin. Infect. Dis. (1996) 23:173–175.
   PubMed Web of Science ®Google Scholar
• BAHR GM, SHAABANS MA, GABRIEL M et al.: Improved immunotherapy for pulmonary tuberculosis with My-cobacterium vaccae. Tubercle (1990) 71:259–266.
   PubMedGoogle Scholar
• A new interesting TB preventative approach with M. vaccae.
   Google Scholar
• ONYEBUJOH PC, ABDULMUMINI T. ROBINSON S, ROOK AW, STANDFORD JL: Immunotherapy with Mycobac-terium vaccae as an addition to chemotherapy for the treatment of pulmonary tuberculosis under difficult conditions in Africa. Respir. Med. (1995) 89:199–207.
   PubMed Web of Science ®Google Scholar
• The first clinical results of M. vaccae in combination with chemo-therapy.
   Google Scholar
• BLASCHKE TF, SKINNER MI-I: The clinical pharmacoki-netics of rifabutin. Clin. Infect. Dis. (1996) 22(1) :S15–22.
   PubMedGoogle Scholar
• ARIOLI V, BERTI M, CARNITI C, RANDISI E, ROSSI E, SCOTTI R: Antibacterial activity of DL473, a new synthetic ri-famycin derivative. J. Antibiotic (1981) 34:1026–1034.
   PubMed Web of Science ®Google Scholar
• LEE HS, SKIN HS, HAN SS, ROL JK: High performance liquid chromatographic determination of rifapentine in serum using column switching. J. Chromatogr. (1992) 574:175–178.
   PubMed Web of Science ®Google Scholar
• BAOHONG JT, TRUFFOT-PERNOT C, LACROIX C et al.: Effectiveness of rifampin, rifabutin and rifapentin for preventive therapy of tuberculosis in mice. Am. Rev. Resp. Dis. (1993) 148:1541–1548.
   PubMed Web of Science ®Google Scholar
• BIYA Y, LIZHEN Z, FENGYING Z: A clinical comparative study of Chinese-made rifapentine on chemotherapy of tuberculosis in Chinese with English abstract. China Antibiotic (1992) 17–313 [Quoted by CAROSI G, MATTO-CELLI A: Prophylaxis of tuberculosis in Europe. Ongo-ing Research. Clin. Infect. Dis. (1996) 22(1):S55–60[.
   Google Scholar
• DHILLON J, DICKINSON JM, GUY IA, NG TK, MITCHINSON DA: Activity of two long-acting rifarnpicins, rifapentine and FC 22807, in experimental murine tuberculosis. Tubercle Lung Dis. (1992) 73:116–123.
   PubMedGoogle Scholar
• DICKINSON JM, MITCHISON DA DICKINSON JM, MITCHISON DA: In vitro activities against mycobacteria of two long-acting rifamycins, FCE 22807 and CGP 401469A (SPA-S-566). Tubercle (1990) 71:100–115.
   Google Scholar
• BRUZZESE T, CREDO A, DELL'ACQUA E, DI NARDO A, GOI A: New long-acting 3-azinomethyirifamycins. Farm. Ed. Sci. (1986) 41:196–204.
   PubMedGoogle Scholar
• SAITO H, TOMIOKA H, SAITO K et al.: In vitro antimyco-bacterial activities of newly synthesized benzoxazinori-famycins. Antimicrob. Agent Chemother. (1991) 35:542–547.
   PubMed Web of Science ®Google Scholar
• MOR N, SIMON B, HEIFETS L: Bacteriostatic and bacteri-cidal activities of benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis and Mycobac-terium avium in human macrophages. Antimicrob. Agents Chemother. (1996) 46:1428–1450.
   Google Scholar
• The Aminoglycosides. Microbiology, Clinical Use and Toxicol-ogy. Whelton A, Neu HC (Eds.), Marcel Dekker, Inc. New York (1992).
   Google Scholar
• KANYOK TP, VENKATA REDDY M, CHINNASWAMY J, DANZIGER LH, GANGADHARAM PRJ: Activity of ami-nosidine (paromomycin) for Mycobacterium tubercu-losis and Mycobacterium avium. J. Antimicrob. Chemother. (1994) 33:323–327.
   PubMed Web of Science ®Google Scholar
• KANYOK TP, VENKATA REDDY M, CHINNASWAMY J, DANZIGER LH, GANGADHARAM PRJ: In vitro activity of paromomycin against susceptible and multidrug resis-tant Mycobacterium tuberculosis and M avium com-plex. Antimicrob. Agents Chemother. (1994) 38:170–178.
   PubMed Web of Science ®Google Scholar
• KANYOK TP, KILLIAN AD, RODVOLD KA, DANZIGER LH: Pharmacokinetics of intramuscularly administered arninosidine in healthy subjects. Antimicrob. Agents Chemother. (1997) 41:982–986.
   PubMed Web of Science ®Google Scholar
• Quinol one Antimicrobial Agents Second Edition. Hooper DC, Wolfson JS (Eds.), American Society for Microbiology, Wash-ington, DC (1993).
   Google Scholar
• TRUFFOT-PERNOT C, JI B, GROSSET J et al.: Activity of pefloxacin and ofloxacin against mycobacteria: in vitro and mouse experiments. Tubercle (1991) 72:57–64.
   PubMedGoogle Scholar
• LEYSEN DC, HAEMERS A, PATTYN SR: Mycobacteria and new quinolones. Antimicrob. Agents Chemother. (1989) 33:1–5.
   PubMed Web of Science ®Google Scholar
• COLLINS CH, UTTELY A: In vitro susceptibility of myco-bacteria to ciprofloxacin.J. Antimicrob. Chemother. (1985) 16:575–580.
   PubMed Web of Science ®Google Scholar
• KENNEDY N, BERGER L, CURRAM J et al.: Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tubercu-losis. Clin. Infect. Dis. (1996) 22:827–833.
   PubMed Web of Science ®Google Scholar
• SAITO H, SATO K, TOMIOKA H, DEKIO S: In vitroantimy-cobacterial activity of a new quinolone, levofloxacin (DR-3355). Tubercle Lung Dis. (1995) 76:377–380.
   PubMedGoogle Scholar
• KLEMENS SP, SHARPE CA, ROGGE MC, CYNAMON MH: Activity of levofloxacin in a murine model of tubercu-losis. Antimicrob. Agents Chemother. (1994) 38:1470–1479.
   PubMedGoogle Scholar
• YEW WW, AU KF, LEE J, CHAN CH: Levofloxacin in the treatment of drug-resistant tuberculosis. Int. J. Tuber. and Lung Dis. (1997) 1:89.
   PubMed Web of Science ®Google Scholar
• GOA KL, BRYSON HM, MARKHAM A: Sparfloxacin: an-tibacterial activity, pharmacokinetic properties, clini-cal efficacy and tolerability in lower respiratory tract infections. Drugs (1997) 53:700–725.
   PubMed Web of Science ®Google Scholar
• WOODCOCK JM, ANDREWS JM, BOSVVELL FJ, BRENWALDNP, WISE R: In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob. Agents Chemother. (1997) 41:101–106
   PubMed Web of Science ®Google Scholar
• TODD PA, BENFIELD P: Amoxicillin/clavulanic acid. An update of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs (1990) 39:264–307.
   Google Scholar
• NADLER JP, BERGER J, NORD JA: Amoxicillin-clavulanic acid for treating drug-resistant tuberculosis. Chest (1991) 1021–1026.
   PubMedGoogle Scholar
• BALFOUR JA, BRYSON HM, BROGDEN RN: lmipenem/cilastatin: an update of its antibacterial ac-tivity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections. Drugs (1996) 51: 99–136.
   PubMed Web of Science ®Google Scholar
• WATT B, EDWARDS JR, RAYNER A, GR NDEY AJ, HARRIS G: In vitro activity meropenem and imipenem against mycobacteria: development of a daily antibiotic dosing schedule. Tubercle Lung Dis. (1992) 73:134–136.
   PubMedGoogle Scholar
• WISEMAN LR, WAGSTAFF AJ, BROGDEN RN, BRYSON HM: Meropenem. A review of its antibacterial activity, phar-macokinetic properties and clinical efficacy. Drugs (1995) 50:73–101.
   Google Scholar
• JANNATH R, REDDY MV, KAILASOM S, O'SULLIVAN JK, GANGADHARAM RJ: Therapeutic activity of clofazimine and its analogues against Mycobacterium tuberculosis. Am. J. Respir. Crit. Care Med. (1995) 151:1083–1086.
   PubMed Web of Science ®Google Scholar
• ASHTEKAR DR, COSTA-PEREIRA R, NAGRAJAN K et al: Invitro and in vivo activity of nitroimidazole CGI 17341 against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. (1993) 37:183–186.
   PubMed Web of Science ®Google Scholar
• ASHTEKAR DR, COSTA-PEREIRA R, ABER R et al.: In vitro and in vivo antituberculous activity of oxazolidinone DuP 721 and in vitro imidazole CGI 17341 : novel families of antimicrobics. Program Abs 29th ICAAC (1989). Abstract 889.
   Google Scholar
• ASHTEKAR DR, COSTA-PEREIRA R, AJJER R, VISHVANATHAN N, RITTEL W: Oxazolidinones, a new class of synthetic antituberculous agents: in vitro and in vivo activity of DuP 721 against Mycobacterium tuberculosis. Diagn. Nlicrobiol Infect. Di. (1991) 14:465–471.
   PubMed Web of Science ®Google Scholar
• CROWLE AJ, DOWAS GS, MAY MH: Chlorpromazine: adrug potentially useful for treating mycobacterial infec-tions. Chemotherapy (1992) 38:410–419.
   PubMed Web of Science ®Google Scholar
• JAGANNATH C, ALLANDER HS, HUNTER RL: Activities ofpoloxamer CRL 8131 against Mycobacterium tubercu-losis in vitro and in vivo. Antimicrobial Agents Chem other. (1995) 39:1349–135453
   PubMed Web of Science ®Google Scholar
• PETERSON PK, GEKKER G, BORZNEMANNAN M, CHAT-TERJCE D: Thalidomide inhibits lip oarabinomannan-in-duced upregulation of human immunodeficiency virus expression. Antimicrob. Agents Chem other. (1995) 39:2807.
   PubMedGoogle Scholar
• GUARNACCA GW, VANCE EA, WU JJ, REMOLD HG, KAZAN-JIAN PH: lnterieukin-12 enhances antigen specific pro-liferation of peripheral blood mononuclear cells from 'IN-positive patients and negative donors in response to Mycobacterium avium. AIDS (1994) 8: 1413–1419.
   PubMedGoogle Scholar
• JACOBSON M, HARDY D: Phase I trial of recombinant1L-12 in HIV-infected subjects. Third Int. Conf. Retrovirus Opportunistic Infect. Washington (1996). Abstract 309.
   Google Scholar